The dual action of Tirzepatide effectively reduces caloric intake while improving glucose metabolism, which explains why the SURMOUNT-1 trial data showed up to a 22.5% mean weight reduction at the 72-week mark
If we can make the atrium a less favorable environment for AFib, ablation has a better chance to work. Next Steps: Larger Trials and Broader Applications of GLP1 Therapy While LEAF was a relatively small, singlecenter study, the magnitude of benefit observed has generated interest in larger trials to confirm the findings and determine optimal timing and duration of GLP1 therapy
It is part of a new class of incretin-based medications and functions as a triple agonist, unlike its peers like tirzepatide, which act only as dual agonists
We are seeing a lot of women and older people
When you take a GLP-1 agonist, food stays in your stomach longer
Safety Profile: Observed effects are consistent with the incretin class, including manageable gastrointestinal transitions such as nausea or mild digestive changes